Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile
Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of
achieving comparable cure rates to standard of care, but reducing rates of recurrent disease.
A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these
attributes with a comparable safety profile. A high fecal concentration of ridinilazole and
little systemic exposure were noted.
The rationale for this phase 3 study is to confirm the improvement in sustained clinical
response of CDI over vancomycin and to compare the safety and tolerability of ridinilazole to
that of vancomycin.
Ridinilazole plasma concentration will be assessed in a subset of patients.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.